Literature DB >> 9312040

The three-dimensional solution structure of the matrix protein from the type D retrovirus, the Mason-Pfizer monkey virus, and implications for the morphology of retroviral assembly.

M R Conte1, M Klikova, E Hunter, T Ruml, S Matthews.   

Abstract

The Mason-Pfizer monkey virus (M-PMV) is the prototype of the type D retroviruses. In type B and D retroviruses, the Gag protein pre-assembles before association with the membrane, whereas in type C retroviruses (lentiviruses, BLV/HTLV group) Gag is targeted efficiently to the plasma membrane, where the particle formation occurs. The N-terminal domain of Gag, the matrix protein (MA), plays a critical role in determining this morphogenic difference. We have determined the three-dimensional solution structure of the M-PMV MA by heteronuclear nuclear magnetic resonance. The protein contains four alpha-helices that are structurally similar to the known type C MA structures. This similarity implies possible common assembly units and membrane-binding mechanisms for type C and B/D retroviruses. In addition to this, the interpretation of mutagenesis data has enabled us to identify, for the first time, the structural basis of a putative intracellular targeting motif.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9312040      PMCID: PMC1170213          DOI: 10.1093/emboj/16.19.5819

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  25 in total

1.  Implications for viral uncoating from the structure of bovine enterovirus.

Authors:  M Smyth; J Tate; E Hoey; C Lyons; S Martin; D Stuart
Journal:  Nat Struct Biol       Date:  1995-03

2.  Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production.

Authors:  E O Freed; J M Orenstein; A J Buckler-White; M A Martin
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

3.  Three-dimensional structure of the HTLV-II matrix protein and comparative analysis of matrix proteins from the different classes of pathogenic human retroviruses.

Authors:  A M Christensen; M A Massiah; B G Turner; W I Sundquist; M F Summers
Journal:  J Mol Biol       Date:  1996-12-20       Impact factor: 5.469

4.  Refined solution structure of p17, the HIV matrix protein.

Authors:  S Matthews; P Barlow; N Clark; S Kingsman; A Kingsman; I Campbell
Journal:  Biochem Soc Trans       Date:  1995-11       Impact factor: 5.407

5.  Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein.

Authors:  M A Massiah; M R Starich; C Paschall; M F Summers; A M Christensen; W I Sundquist
Journal:  J Mol Biol       Date:  1994-11-25       Impact factor: 5.469

6.  Crystal structure of SIV matrix antigen and implications for virus assembly.

Authors:  Z Rao; A S Belyaev; E Fry; P Roy; I M Jones; D I Stuart
Journal:  Nature       Date:  1995-12-14       Impact factor: 49.962

7.  Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly.

Authors:  P Spearman; J J Wang; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

8.  Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria.

Authors:  M Klikova; S S Rhee; E Hunter; T Ruml
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

9.  Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly.

Authors:  C P Hill; D Worthylake; D P Bancroft; A M Christensen; W I Sundquist
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

10.  The solution structure of the bovine leukaemia virus matrix protein and similarity with lentiviral matrix proteins.

Authors:  S Matthews; M Mikhailov; A Burny; P Roy
Journal:  EMBO J       Date:  1996-07-01       Impact factor: 11.598

View more
  33 in total

1.  Crystal structure of the matrix protein VP40 from Ebola virus.

Authors:  A Dessen; V Volchkov; O Dolnik; H D Klenk; W Weissenhorn
Journal:  EMBO J       Date:  2000-08-15       Impact factor: 11.598

2.  Analysis of Mason-Pfizer monkey virus Gag particles by scanning transmission electron microscopy.

Authors:  S D Parker; J S Wall; E Hunter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Molecular organization of Mason-Pfizer monkey virus capsids assembled from Gag polyprotein in Escherichia coli.

Authors:  Milan V Nermut; Patrick Bron; Daniel Thomas; Michaela Rumlova; Tomas Ruml; Eric Hunter
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Evolution of feline immunodeficiency virus Gag proteins.

Authors:  Evan Burkala; Mary Poss
Journal:  Virus Genes       Date:  2007-01-30       Impact factor: 2.332

5.  Identification of a conserved residue of foamy virus Gag required for intracellular capsid assembly.

Authors:  S W Eastman; M L Linial
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 6.  Virus maturation by budding.

Authors:  H Garoff; R Hewson; D J Opstelten
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

7.  Efficient HIV-1 replication can occur in the absence of the viral matrix protein.

Authors:  H Reil; A A Bukovsky; H R Gelderblom; H G Göttlinger
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

8.  Solution structure and backbone dynamics of Mason-Pfizer monkey virus (MPMV) nucleocapsid protein.

Authors:  Y Gao; K Kaluarachchi; D P Giedroc
Journal:  Protein Sci       Date:  1998-11       Impact factor: 6.725

9.  An early stage of Mason-Pfizer monkey virus budding is regulated by the hydrophobicity of the Gag matrix domain core.

Authors:  Elizabeth Stansell; Ewan Tytler; Mark R Walter; Eric Hunter
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Multimerization of the p12 domain is necessary for Mason-Pfizer monkey virus Gag assembly in vitro.

Authors:  Zdenek Knejzlík; Zdena Smékalová; Tomás Ruml; Michael Sakalian
Journal:  Virology       Date:  2007-05-09       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.